Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 3

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 2
Chunk 3
---
%Net Sales$4,663 $3,856 20.9%

MedSurg

Endoscopy 

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions with innovative, less-invasive technologies. Net sales of Endoscopy products of $673 million during the first quarter of 2025 represented 14 percent of our consolidated net sales. Endoscopy net sales increased $30 million, or 4.7 percent, during the first quarter of 2025, compared to the prior year period. During the first quarter of 2025, this increase included operational net sales growth of 5.9 percent and the negative impact of 120 basis points from foreign currency fluctuations, compared to the prior year period. Operational net sales growth during the first quarter of 2025 included organic net sales growth of 5.5 percent and the positive impact of 40 basis points from our acquisition of the endoluminal vacuum therapy portfolio of Braun during the first quarter of 2024.

Organic net sales growth was primarily driven by our biliary franchise led by our AXIOS™ Stent and Delivery System, and our endoluminal surgery franchise.

Urology

Our Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction and incontinence. Net sales of Urology products of $633 million during the first quarter of 2025 represented 14 percent of our consolidated net sales. Urology net sales increased $120 million, or 23.5 percent, during the first quarter of 2025, compared to the prior year period. During the first quarter of 2025, this increase included operational net sales growth of 24.5 percent and the negative impact of 100 basis points from foreign currency fluctuations, compared to the prior year period. Operational net sales growth during the first quarter of 2025 included organic net sales growth of 4.4 percent and the positive impact of 2,010 basis points from our acquisition of Axonics during the fourth quarter of 2024.

Organic net sales growth was primarily driven by our stone management franchise.

Neuromodulation 

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Net sales of Neuromodulation products of $271 million during the first quarter of